Kapusta Matthew C 4
4 · uniQure N.V. · Filed Jul 7, 2026
Research Summary
AI-generated summary of this filing
uniQure CEO Matthew Kapusta Exercises Options and Sells Shares
What Happened
- Matthew C. Kapusta, CEO and Managing Director of uniQure (QURE), exercised 21,082 stock options on July 2, 2026 at $19.39 per share (total cost $408,780) and sold all 21,082 shares in open-market transactions the same day for aggregate proceeds of approximately $952,051. The transactions were effected under a pre-established Rule 10b5-1 sales plan.
- Net cash received from the sequence (gross sales minus exercise cost) was about $543,271. The reported option had vested in full on January 26, 2022.
Key Details
- Transaction date: July 2, 2026; Form 4 filed July 7, 2026 (appears to be filed after the usual two-business-day deadline).
- Exercise: 21,082 shares at $19.39 each = $408,780 (transaction code M).
- Sales (all on July 2, 2026):
- 9,200 shares at weighted avg $44.43 (range $44.10–$44.80) — $408,756
- 4,282 shares at weighted avg $45.43 (range $45.00–$45.95) — $194,531
- 7,600 shares at weighted avg $45.89 (range $45.48–$46.10) — $348,764
- Total sold: 21,082 shares for ~$952,051.
- Footnotes: F1 indicates sales were under a Rule 10b5-1 plan; F5 notes the option vested on Jan 26, 2022. Several footnotes detail weighted-average price ranges for the multiple sale trades.
- Shares owned after the transaction: not specified in the provided filing details.
Context
- This was effectively a cashless exercise and immediate sale: Kapusta exercised options and sold those same shares the same day, which is typically a liquidity event rather than a directional “buy” signal.
- The use of a 10b5-1 plan means the sales were prearranged; that can reduce (but does not eliminate) the informational content of the sale about the insider’s current view.
- The filing date suggests the Form 4 was submitted after the standard two-business-day reporting window, which may be noted by regulators or investors tracking timeliness.
Insider Transaction Report
Form 4
uniQure N.V.QURE
Kapusta Matthew C
DirectorCEO, Managing Director
Transactions
- Exercise/Conversion
Ordinary Shares
[F1]2026-07-02$19.39/sh+21,082$408,780→ 540,309 total - Sale
Ordinary Shares
[F1][F2]2026-07-02$44.43/sh−9,200$408,756→ 531,109 total - Sale
Ordinary Shares
[F1][F3]2026-07-02$45.43/sh−4,282$194,531→ 526,827 total - Sale
Ordinary Shares
[F1][F4]2026-07-02$45.89/sh−7,600$348,764→ 519,227 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-07-02−21,082→ 0 totalExercise: $19.39Exp: 2028-01-26→ Ordinary Shares (21,082 underlying)
Footnotes (5)
- [F1]The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.48 to $46.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The Stock Option vested in full on January 26, 2022.
Signature
/s/ Christian Klemt, Attorney-in-Fact|2026-07-07